Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms
Case Against Zantac Marketer Could Strike Out On Faulty Research Behind Carcinogen Claim
Whether California court finds Zantac, when marketed containing ranitidine, should have had a Prop 65 label warning could be influenced by dismissal in federal court of class action complaints due to faulty research behind claims that ranitidine causes a carcinogenic substance to form post-production.
